Private Markets, Angel and Secondary Investing, Sacra

Sacra

Private Markets, Angel and Secondary Investing

Bringing transparency to private markets so investors, founders, and employees can build on conviction. Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Capital Markets

<ul><li>In November 2025, Hippocratic AI raised a $126 million Series C led by Avenir Growth at a $3.5 billion valuation.</li><li>Hippocratic AI is a platform that creates AI-powered virtual nurses and care coordinators for health systems to handle routine, non-diagnostic patient interactions.</li><li>The company recently launched an AI Agent App Store where third-party developers and health systems can publish and monetize their own specialized agents, expanding beyond Hippocratic's internally-developed offerings.</li></ul>

In November 2025, Hippocratic AI raised a $126 million Series C led by Avenir Growth at a $3.5 billion valuation.Hippocratic AI is a platform that creates AI-powered virtual nurses and care coordinators for health systems to handle routine, non-diagnostic patient interactions.The company recently launched an AI Agent App Store where third-party developers and health systems can publish and monetize their own specialized agents, expanding beyond Hippocratic's internally-developed offerings.

<ul><li>Sacra estimates that OpenEvidence hit $300M in annualized revenue in July 2026, up from $150M at the end of 2025.</li><li>OpenEvidence grew from $7.9M in annualized revenue at the end of 2024 to $150M at the end of 2025, up approximately 1,800% year-over-year, with reported 90% gross margins.</li><li>OpenEvidence’s latest $250M raise in September 2026 valued the company at $15B, implying approximately 50x its $300M annualized revenue.</li></ul>

Sacra estimates that OpenEvidence hit $300M in annualized revenue in July 2026, up from $150M at the end of 2025.OpenEvidence grew from $7.9M in annualized revenue at the end of 2024 to $150M at the end of 2025, up approximately 1,800% year-over-year, with reported 90% gross margins.OpenEvidence’s latest $250M raise in September 2026 valued the company at $15B, implying approximately 50x its $300M annualized revenue.

United States

AI agents for healthcare providers to perform non-diagnostic, patient-facing clinical tasks

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Hippocratic AI (AI US)

Primer: Hippocratic AI - 05 Nov 2025

AI agents for healthcare providers to perform non-diagnostic, patient-facing clinical tasks

Sacra

Primer: OpenEvidence - 21 Sep 2026

AI copilot for doctors to assist in making critical decisions at the point of care

Sacra

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)